At a Glance
- Company: Gilead Sciences; Kymera Therapeutics (NASDAQ: KYMR)
- Location: Foster City, California (Gilead); Watertown, Massachusetts (Kymera)
- Deal value: $45M option exercise; up to $750M total including royalties
- Focus area: KT-200, oral CDK2 molecular glue degrader for breast cancer and solid tumours
- Next steps: Gilead runs IND-enabling studies; IND filing targeted for 2027
What happened?
Gilead Sciences exercised its exclusive option to license KT-200, Kymera Therapeutics’ first-in-class oral CDK2 molecular glue degrader, triggering a $45 million milestone payment to Kymera on 9 April 2026. The option was originally agreed in June 2025 for a $40 million upfront fee, bringing total payments to date to $85 million against a deal ceiling of $750 million in milestones and tiered royalties.
Why does it matter?
KT-200 is differentiated from the growing class of CDK2 inhibitors — including those in development at Roche and Monte Rosa — because it degrades the kinase rather than merely blocking it. Kymera claims this selectivity avoids CDK1 cross-inhibition, the source of dose-limiting toxicities that have complicated CDK2 inhibitor development and limited achievable exposure. An oral molecular glue that selectively eliminates CDK2 could therefore offer a cleaner, more potent path through breast cancer and other CDK2-driven solid tumours.
Who’s behind it?
Kymera Therapeutics is a pioneer in targeted protein degradation, with its platform spanning PROTACs, molecular glues and related modalities; KT-200 marks the first molecular glue to emerge from its discovery engine. Gilead, freshly integrated from more than $12 billion in recent acquisitions, said this week it is shifting focus to pipeline advancement rather than further large buyouts — making the Kymera option exercise a typical example of the smaller, high-conviction deals it continues to execute.
How was it achieved?
Under the 2025 agreement, Kymera led all research activities to generate a preclinical data package and nominate a mutually agreed development candidate. KT-200 demonstrated low-nanomolar CDK2 degradation in preclinical studies, giving Gilead sufficient confidence to trigger the licence. Gilead now assumes global responsibility for IND-enabling studies, clinical development, manufacturing and commercialisation.
What’s next?
Gilead will run IND-enabling studies with the goal of filing an IND in 2027, aiming to make KT-200 the first Kymera-discovered molecular glue to enter clinical testing. On the same day as the Kymera announcement, Gilead also exercised an option on an oncology target with Cartography Biosciences and announced an expanded oncology collaboration with Tempus AI, signalling that disciplined, targeted dealmaking remains active even as big M&A is paused.
What are people saying?
Nello Mainolfi (Kymera CEO): “KT-200 is expected to be the first molecular glue discovered by Kymera to enter the clinic… potential to transform the therapeutic landscape for patients with cancers that remain difficult to treat.” Flavius Martin (Gilead EVP Research): “MGDs are opening exciting new possibilities… a way to eliminate disease-driving proteins rather than just blocking them.”